Study of Food Effects of VV261 Tablets in Healthy Trial Participants

November 4, 2026 updated by: Vigonvita Life Sciences

This is a single-center, randomized, open-label, three-cycle, self-cross-over study on human pharmacokinetic characteristics under fasting, standard meal, and high-fat meal conditions.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is a single-center, randomized, open-label, three-cycle, self-crossed trial designed with a dosage of 600 mg and a washout period of 8 days. The study is expected to enroll 15 trial participants. The 15 participants will be randomly assigned to three groups:A, B, and C,with 5 participants in each group. In Group A, administration during the first cycle will be performed under fasting conditions; during the second cycle, under standard postprandial conditions; and during the third cycle, under high-fat postprandial conditions. In Group B, administration during the first cycle will be performed under high-fat postprandial conditions; during the second cycle, under fasting conditions; and during the third cycle, under standard postprandial conditions. In Group C, administration during the first cycle will be performed under standard postprandial conditions; during the second cycle, under high-fat postprandial conditions; and during the third cycle, under fasting conditions.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
15

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • China
    • Anhui
      • Hefei, Anhui, China, 230031
        • The First Affiliated Hospital of Anhui Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Aged 18 to 45 years old, males or females;
  2. Males weight no less than 50 kg, females weight no less than 45 kg, with body mass index of 19 to 26 kg/m^2;
  3. Vital signs examination, physical examination, laboratory examination ,electrocardiogram examination chest CT and B-ultrasound of liver, gallbladder, pancreas, spleen, kidney and thyroid results are normal or considered abnormal without clinical significance by the investigator;
  4. Participants who are willing to take proper contraceptive methods during the study and within 3 months after the the last administration;
  5. Participants who are able to understand and follow the study protocol and instructions; participants who have voluntarily decided to participate in this study, and sign the informed consent form.

Exclusion Criteria:

  1. Participants with hypersensitivity to preparation or any of the excipients;
  2. Participants with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy;
  3. Participants with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials;participants with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations/fistulas, gastrointestinal bleeding, or obstruction);participants with previous surgery that may significantly affect the body's metabolic process or safety evaluation of the study drug (such as liver, gallbladder, kidney, splenectomy, gastrointestinal resection or excessive blood loss that affects drug absorption, distribution, metabolism)
  4. Participants with a history of diseases affecting bone marrow hematopoietic function or reducing immunological function (including leukemia, myelodysplastic syndrome, aplastic anemia, systemic lupus erythematosus, rheumatoid arthritis, etc.) or treatment history (tumor chemotherapy or radiotherapy, use of immunosuppressants, etc.);
  5. Participants with a history of spleen diseases;
  6. If any of the following parameters were considered abnormal with clinical significance: white blood cell count, red blood cell count, platelet count, reticulocyte count, and absolute neutrophil count;
  7. If any of the following parameters were considered abnormal with clinical significance: total bilirubin, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase;
  8. Participants who have received blood transfusion or used blood products within 3 months before screening or who have lost more than ≥400 mL of blood due to other reasons (excluding menstruation);
  9. Participants who have participated in clinical trials and received drugs within 3 months before screening;
  10. Participants who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 2 weeks before screening;
  11. Participants who have received vaccination within the first 2 weeks before screening, or planned to receive any vaccine within 1 week after the end of the study;
  12. Participants with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine);
  13. Participants who drink more than 14 standard units or at least twice a day per week within one year before screening,(one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of white wine with 40% alcohol content or 85 mL of red wine with 12% alcohol) or participants with breath alcohol test >0 mg/100 mL;
  14. Participants who smok more than 5 cigarettes a day within one year before screening;
  15. Participants who can't quit smoking or drinking during the trial period;
  16. Participants who are positive for hepatitis B virus surface antigen, hepatitis C virus antibody, treponema pallidum antibody or human immunodeficiency virus antibody (Anti-HIV);
  17. Participants who cannot tolerate blood collection with intravenous indwelling needles or blood fainting;
  18. Participants with lactose intolerance or cannot comply with a uniform diet (such as special dietary requirements, intolerance of standard meals, etc.), Participants who have consumed excessive amounts of strong tea, coffee or caffeinated beverages in the 3 months before screening;
  19. Participants with difficulty in swallowing tablets;
  20. Pregnant or lactating women; participants whose spouses or partners intend to become pregnant, plan sperm or oocyte donation within 3 months after the last dose, or decline to use acceptable effective contraception；
  21. The investigator believes that there are other unsuitable factors to participate this trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: A group
Drug: VV261

A group：600 mg VV261, following an overnight fast of at least 10 hours for Period 1 ;600 mg VV261, administered 30 minutes after the start of a Standard meal for Period 2 ; 600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 3;

Drug: VV261

B group：600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 1 ; 600 mg VV261, following an overnight fast of at least 10 hours for Period 2 ; 600 mg VV261, administered 30 minutes after the start of a Standard meal for Period 3;

Drug: VV261

C group：administered 30 minutes after the start of a Standard meal for Period 1;600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 2 ; 600 mg VV261, following an overnight fast of at least 10 hours for Period 3 ;
Experimental: B group
Drug: VV261

A group：600 mg VV261, following an overnight fast of at least 10 hours for Period 1 ;600 mg VV261, administered 30 minutes after the start of a Standard meal for Period 2 ; 600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 3;

Drug: VV261

B group：600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 1 ; 600 mg VV261, following an overnight fast of at least 10 hours for Period 2 ; 600 mg VV261, administered 30 minutes after the start of a Standard meal for Period 3;

Drug: VV261

C group：administered 30 minutes after the start of a Standard meal for Period 1;600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 2 ; 600 mg VV261, following an overnight fast of at least 10 hours for Period 3 ;
Experimental: C group
Drug: VV261

A group：600 mg VV261, following an overnight fast of at least 10 hours for Period 1 ;600 mg VV261, administered 30 minutes after the start of a Standard meal for Period 2 ; 600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 3;

Drug: VV261

B group：600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 1 ; 600 mg VV261, following an overnight fast of at least 10 hours for Period 2 ; 600 mg VV261, administered 30 minutes after the start of a Standard meal for Period 3;

Drug: VV261

C group：administered 30 minutes after the start of a Standard meal for Period 1;600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 2 ; 600 mg VV261, following an overnight fast of at least 10 hours for Period 3 ;

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Incidence of Treatment-Emergent Adverse Events
Time Frame: Baseline to 7days after the last administration

Incidence of Treatment-Emergent Adverse Events
Baseline to 7days after the last administration
Cmax
Time Frame: Baseline to 96 hours after the last administration

Maximum observed plasma concentration
Baseline to 96 hours after the last administration
Tmax
Time Frame: Baseline to 96 hours after the last administration

Time at which Cmax occurs
Baseline to 96 hours after the last administration
AUC0-t
Time Frame: Baseline to 96 hours after the last administration

Area under the plasma concentration time curve from time zero to the last measurable concentration
Baseline to 96 hours after the last administration
AUC0-∞
Time Frame: Baseline to 96 hours after the last administration

Area under the plasma concentration-time curve from time zero to infinity
Baseline to 96 hours after the last administration
t1/2
Time Frame: Baseline to 96 hours after the last administration

Half life of elimination
Baseline to 96 hours after the last administration
CL/F
Time Frame: Baseline to 96 hours after the last administration

Apparent clearance
Baseline to 96 hours after the last administration
mean Resident Time
Time Frame: Baseline to 96 hours after the last administration

Mean Resident Time from time zero to infinity/the last
Baseline to 96 hours after the last administration
Vd/F
Time Frame: Baseline to 96 hours after the last administration

Apparent volume of distribution during the terminal phase
Baseline to 96 hours after the last administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Vigonvita Life Sciences

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Huan Zhou, The First Affiliated Hospital of Anhui Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 9, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 30, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 4, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 4, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 10, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 4, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • VV261-03

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings